INFANRIX Rx

Indications for INFANRIX:

Diphtheria, tetanus, and pertussis immunization in children 6 weeks up to 7 years of age (before 7^th birthday).

Adult:

Not recommended.

Children:

Each dose is 0.5mL IM. Primary series: Give 1^st dose preferably at 2 months of age (may give as early as 6 wks of age); then give 2^nd dose 4–8 wks later, then give 3^rd dose 4–8 wks later, then give 4^th dose at 15–20 months of age (6–12 months after 3^rd dose); may give 5^th dose at 4–6 yrs of age, unless 4^th dose was given after 4^th birthday. Or, may be used to complete a DTaP vaccination series initiated with Pediarix.

Contraindications:

Anaphylaxis associated with any previous diphtheria, tetanus, pertussis vaccine. Encephalopathy within 7 days of a previous pertussis vaccine. Progressive neurologic disorders (eg, infantile spasms, uncontrolled epilepsy, progressive encephalopathy).

Warnings/Precautions:

Guillain-Barre syndrome within 6 weeks of previous tetanus vaccination. Fever (≥105°F within 48 hours), persistent inconsolable crying (≥3 hours within 48 hours), shock (within 48 hours), or seizures (within 3 days) after previous pertussis vaccine: see literature. Seizure risk: may give antipyretics. Latex allergy (prefilled syringes). Have epinephrine available. Pregnancy (Cat.C): not applicable.

Pharmacological Class:

DTaP.

Interactions:

Concomitant vaccines: see literature. Immunosuppressants (eg, radiation, chemotherapy, high-dose steroids): may get suboptimal response.

Adverse Reactions:

Local reactions, fever, irritability/fussiness, crying, drowsiness, loss of appetite, vomiting, diarrhea.

Note:

Report adverse events to VAERS at (800) 822-7967 and to GlaxoSmithKline at (888) 825-5249.

How Supplied:

Single-dose vials—10; Single-dose prefilled Tip-Lok syringe—5 (without needles)